Posts Tagged ‘NTDs’

A Global Strategy to Eliminate Blinding Trachoma, A Disease Targeted by END7

December 19th, 2011

By: Elizabeth Kurylo, Communications manager, International Trachoma Initiative

Eliminating a disease is no small task. It helps to have a detailed plan. Partners working to eliminate blinding trachoma, one of the seven neglected tropical diseases targeted by END7, have such a plan. It’s called 2020 INSight: The End in Sight.

Produced by the International Coalition for Trachoma Control (ICTC), 2020 INSight is a global strategic plan with crucial next steps toward trachoma elimination by 2020.More than 2 million people are either blind or suffer excruciating pain because of trachoma. It makes one person experience severe sight loss every four minutes and blinds four people every hour.  Over 4.6 million are in the final, painful stages of this eye disease and require surgery to prevent them from going blind. It is endemic in at least 59 countries, in areas with limited access to water and sanitation.

A coordinated effort by governments, nongovernmental organizations, donors and other stakeholders is urgently needed to achieve the goal. Crucial next steps include the following:

  • Survey districts where trachoma is suspected to be endemic, so intervention can begin;
  • Dramatically improve access to clean water and latrines;
  • Increase global funding for trachoma control, including implementation of the SAFE strategy (Surgery, Antibiotics, Facial cleanliness, Environmental improvement);
  • Train teachers and other community leaders about facial cleanliness and better hygiene so they can spread the message in their communities;
  • Quickly address the backlog of 4.6 million people who need surgery to prevent blindness;
  • Identify support for more mass drug administration (MDA) programs to provide about 380 million more antibiotic treatments.

More than 80 percent of the burden of active trachoma is concentrated in 14 countries, where immediate action is needed. Eliminating the disease in Africa alone would boost the continent’s gross domestic product (GDP) 20-30 percentage points based on conservative annual productivity loss estimates.

Since 1998, Pfizer Inc has donated more than 225 million doses of the antibiotic Zithromax® to treat and prevent blinding trachoma. The International Trachoma Initiative (ITI) manages the distribution of the medicine.

Get your copy of 2020 INSight at the ICTC website.

 

Tropical Disease Experts Urge Integration of NTD and HIV/AIDS Interventions

December 19th, 2011

At this year’s American Society of Tropical Medicine and Hygiene (ASTMH) conference, experts emphasized the need to integrate neglected tropical disease (NTD) and HIV/AIDS interventions. Many of those who suffer from NTDs are also infected with HIV, and addressing both diseases with one intervention would actually be cost-effective and more clinically beneficial. Below is an article published by ASTMH that describes in depth the benefits of integration:

Global HIV/AIDS prevention and treatment efforts are missing a major opportunity to significantly improve health conditions in poor countries by simply adding low-cost care for the many other chronic and disabling diseases routinely afflicting and often killing these same patients, according to a panel of disease experts who spoke at the annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).

“People want better health; they do not understand why we silo diseases,” said Judd Walson, a global health and infectious disease expert at the University of Washington. “If you die from malaria, you don’t care that your HIV was treated. Communities want us to leverage the resources we have to treat and prevent disease as effectively as possible.”

Walson and his colleagues on the panel noted that many victims of HIV/AIDS also typically suffer from one or more of about 17 neglected, but burdensome, tropical diseases often called “diseases of poverty” because they prey on the “bottom billion”—the world’s poorest people. They include ailments such as trachoma, schistosomiasis, lymphatic filariasis, leishmaniasis, Chagas disease and onchocerciasis, all of which are either insect-borne disease, bacterial infections, or caused by parasitic worms. Click here to continue reading.

We have a new look…

December 9th, 2011

We’re excited to share with you our brand new Global Network for Neglected Tropical Diseases website! We’ve worked hard to create a brand new site that presents the same information and resources for all your NTD needs in a cleaner, more streamlined manner. Click here to check out the newly designed site, or click the image below:

Visceral leishmaniasis/HIV co-infection in East Africa

December 8th, 2011

By: Julien Potet, Neglected Tropical Diseases Policy Advisor at Médecins Sans Frontières’ Campaign for Access to Essential Medicines

Today is the last day of the 16th International Conference on AIDS and STIs in Africa (ICASA), in Addis Ababa, Ethiopia. Ethiopia is a hotspot for cases of co-infection between HIV and visceral leishmaniasis: around one-third of patients with visceral leishmaniasis in North-West Ethiopia are also HIV-positive. With ICASA this year being held in the heart of where most cases of HIV and visceral leishmaniasis occur, it presents a unique opportunity to highlight both the danger of visceral leishmaniasis among the HIV community, and the measures to be taken to address this deadly co-infection.

Visceral leishmaniasis endemic areas in East Africa.

Visceral leishmaniasis, also known as kala azar, is a vector-borne neglected parasitic disease that is fatal if left untreated. It affects between 250,000 and 300,000 people each year worldwide. In East Africa, cases of visceral leishmaniasis are driven by many factors, including the weakness of health systems, the displacement of non-immune populations and the HIV pandemic.

Visceral leishmaniasis can not be fully cured in people living with HIV in East Africa. Relapses are almost inevitable and people living with HIV become more drug-unresponsive with each subsequent relapse. But successful treatment of the first episode of visceral leishmaniasis and early initiation of antiretroviral therapy may delay and reduce relapses. Medecins Sans Frontieres (MSF) has found that customised treatment for visceral leishmaniasis in HIV-positive people can improve their survival rates over time. » Read more: Visceral leishmaniasis/HIV co-infection in East Africa